Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, Bevacizumab and Irinotecan in Recurrent Glioblastoma
NCT00463073Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Aug 2006
- Primary completion
- Dec 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in glioblastoma (GBM), sponsored by Rigshospitalet. Started Aug 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00463073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00463073.